Skip to main content
SpringerLink
Log in

Adamantiades-Behçet Disease

  • Chapter
European Handbook of Dermatological Treatments

Abstract

Adamantiades-Behçet disease is a multisystem inflammatory disease of unknown etiology, classified as systemic vasculitis involving all types and sizes of blood vessels and characterized clinically by recurrent oral aphthous and genital ulcers, skin lesions, and iridocyclitis/posterior uveitis, occasionally accompanied by arthritis and vascular, gastrointestinal, neurologic, or other manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet’s disease. Haematologica. 1980;65:399.

    CAS  PubMed  Google Scholar 

  • Alpsoy E. Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005;23:532.

    CAS  PubMed  Google Scholar 

  • Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet’s disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467.

    Article  CAS  Google Scholar 

  • Altenburg A, Papoutsis N, Orawa H, et al. Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany – Current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges. 2006;4:49.

    Article  Google Scholar 

  • Altenburg A, Abdel-Naser B, Abdallah M, Seeber H, Zouboulis CC. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol. 2007;21:1019–26.

    Article  CAS  Google Scholar 

  • Atmaca LS, Yalçindağ FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet’s disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:451.

    Article  CAS  Google Scholar 

  • Azizlerli G, Koese AK, Sarica R, et al. Prevalence of Behçet’s disease in Istanbul. Turkey Int J Dermatol. 2003;42:803.

    Article  Google Scholar 

  • BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988;20 suppl 4:136.

    CAS  PubMed  Google Scholar 

  • Coskun B, Öztürk P, Saral Y. Are erythema nodosum-like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet’s disease? Int J Clin Pract. 2005;59:69.

    Article  CAS  Google Scholar 

  • Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542.

    Article  CAS  Google Scholar 

  • Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet’s syndrome: a randomized double-blind trial. Br J Rheumatol. 1988;27:300.

    Article  CAS  Google Scholar 

  • Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet’s syndrome: a randomized double-blind trial. Br J Rheumatol. 1998;27:300.

    Article  Google Scholar 

  • de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61:1287.

    Article  Google Scholar 

  • Durrani K, Papaliodis GN. The genetics of Adamantiades-Behcet’s disease. Semin Ophthalmol. 2008;23:73.

    Article  CAS  Google Scholar 

  • Escudier M, Bagan J, Scully C. Behçet’s disease (Adamantiades syndrome). Oral Dis. 2006;12:78.

    Article  CAS  Google Scholar 

  • Fietta P. Behçet’s disease: familial clustering and immunogenetics. Clin Exp Rheumatol. 2005;23 suppl 38:S96.

    CAS  PubMed  Google Scholar 

  • Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology (Oxford). 2007;46:1570.

    Article  CAS  Google Scholar 

  • Gül A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:81.

    Article  Google Scholar 

  • Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443.

    Article  CAS  Google Scholar 

  • Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68:1528.

    Article  CAS  Google Scholar 

  • Hirohata S, Kikutchi H. Behçet’s disease. Arthritis Res Ther. 2003;5:139.

    Article  CAS  Google Scholar 

  • International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078.

    Google Scholar 

  • International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD), Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS, Ali AA, Altenburg A, Arromdee E, Baltaci M, Bastos M, Benamour S, Ben Ghorbel I, Boyvat A, Carvalho L, Chen W, Ben-Chetrit E, Chams-Davatchi C, Araújo Correia J, Crespo J, Dias C, Dong Y, Paixão-Duarte F, Elmuntaser K, Elonakov AV, Graña Gil J, Haghdoost A-A, Hayani RF, Houman H, Isayeva AR, Jamshidi AR, Kaklamanis P, Kumar A, Kyrgidis A, Madanat W, Nadji A, Namba K, Ohno S, Olivieri I, Vaz Patto J, Pipitone N, de Queiroz MV, Ramos F, Resende C, Rosa CM, Salvarani C, Serra MJ, Shahram F, Shams H, Sharquie KE, Sliti-Khanfir M, Tribolet de Abreu T, Vasconcelos C, Vedes J, Wechsler B, Cheng YK, Zhang Z, Ziaei N. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.

    Article  Google Scholar 

  • Jorizzo JL, Abernethy JL, White WL, et al. Mucocutaneous criteria for the diagnosis of Behçet’s disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol. 1995;32:968.

    Article  CAS  Google Scholar 

  • Kaneko F, Oyama T, Sato M et al. Behçet’s disease and diseases for its differential diagnosis in dermatology. An annual report of the Behçet’s Disease Research Committee of Japan, 1999, p 128.

    Google Scholar 

  • Kiliç H, Zeytin HE, Korkmaz C, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet’s syndrome. Rheumatology (Oxford). 2009;48:1388.

    Article  Google Scholar 

  • Krause L. Morbus Adamantiades-Behcet. Ophthalmologe. 2005;102:329.

    Article  CAS  Google Scholar 

  • Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896.

    CAS  PubMed  Google Scholar 

  • Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989;1(8647):1093.

    Article  CAS  Google Scholar 

  • Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford). 2006;45:348.

    Article  CAS  Google Scholar 

  • Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4:19.

    Article  CAS  Google Scholar 

  • McCarty MA, Garton RA, Jorizzo JL. Complex aphthosis and Behçet’s disease. Dermatol Clin. 2003;21:41.

    Article  Google Scholar 

  • Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98.

    CAS  PubMed  Google Scholar 

  • Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy of azapropazone in the acute arthritis of Behcet’s syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol. 1995;13:493.

    CAS  PubMed  Google Scholar 

  • Nanke Y, Kamatani N, Okamoto T, et al. Irsogladine is effective for recurrent oral ulcers in patients with Behçet’s disease: an open-label, single-centre study. Drugs R D. 2008;9:455.

    Article  CAS  Google Scholar 

  • Oh SH, Han EC, Lee JH, et al. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease. Clin Exp Dermatol. 2009;34:e208.

    Article  CAS  Google Scholar 

  • Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241.

    Article  CAS  Google Scholar 

  • Papoutsis N, Bonitsis N, Altenburg A et al. HLA-antigens and their importance as prognostic-marker in Adamantiades-Behçet’s disease (ABD) – is HLA-Bw4 a new prognostic marker? Abstracts of the 14th International Conference on Behçet’s disease, London, UK, 2010, p 163.

    Google Scholar 

  • Pipitone N, Olivieri I, Cantini F, et al. New approaches in the treatment of Adamantiades-Behçet’s disease. Curr Opin Rheumatol. 2006;18:3.

    Article  CAS  Google Scholar 

  • Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698.

    Article  CAS  Google Scholar 

  • Sakamoto M, Akazawa K, Nisioka Y, et al. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102:317.

    Article  CAS  Google Scholar 

  • Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet’s disease: review and basis for recommendations. Rheumatology (Oxford). 2007;46:736.

    Article  CAS  Google Scholar 

  • Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267.

    Article  CAS  Google Scholar 

  • Suzuki Kurokawa M, Suzuki N. Behçet’s disease. Clin Exp Med. 2004;4:10.

    Article  CAS  Google Scholar 

  • Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23:395.

    Article  CAS  Google Scholar 

  • Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s disease. N Engl J Med. 1990;322:281.

    Article  CAS  Google Scholar 

  • Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686.

    Article  CAS  Google Scholar 

  • Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci. 2003;60:1903.

    Article  CAS  Google Scholar 

  • Zouboulis CC. Adamantiades-Behçet’s disease. In: Katsambas AD, Lotti TM, editors. European Handbook of Dermatological Treatments. 2nd ed. Berlin Heidelberg: Springer; 2003a. p. 16.

    Chapter  Google Scholar 

  • Zouboulis CC. Morbus Adamantiades-Behçet. In: Mrowietz U, editor. Ciclosporin in der Dermatologie. Stuttgart: Thieme; 2003b. p. 38.

    Google Scholar 

  • Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behçet’s disease. J Invest Dermatol. 2002;119:201.

    Article  CAS  Google Scholar 

  • Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet’s disease. Med Microbiol Immunol. 2003;192:149.

    Article  CAS  Google Scholar 

  • Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet’s disease with systemic interferon alfa. Arch Dermatol. 1998;134:1010.

    Article  CAS  Google Scholar 

  • Zouboulis CC. Epidemiology of Adamantiades-Behçet’s disease. In: Zierhut M, Ohno S, editors. Immunology of Behçet’s disease. Lisse: Swets & Zeitlinger; 2003c. p. 1.

    Google Scholar 

  • Zouboulis CC, Turnbull JR, Martus P. Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet’s disease. Adv Exp Med Biol. 2003a;528:123.

    Article  Google Scholar 

  • Zouboulis CC, Kötter I, Djawari D, et al. Current epidemiological data from the German Registry of Adamantiades-Behçet’s disease. Adv Exp Med Biol. 2003b;528:43.

    Article  Google Scholar 

Further Reading

  • Bawazeer A, Raffa LH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010;18:226.

    Article  CAS  Google Scholar 

  • Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet’s disease. Inflamm Bowel Dis. 2008;14:1259.

    Article  Google Scholar 

  • Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161.

    Article  CAS  Google Scholar 

  • Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285.

    Article  CAS  Google Scholar 

  • Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474.

    Article  CAS  Google Scholar 

  • Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008;14:396.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany

    Christos C. Zouboulis

Authors
  1. Christos C. Zouboulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christos C. Zouboulis .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Andreas Syggros Hospital University of Athens, Athens, Greece

    Andreas D. Katsambas  & Clio Dessinioti  & 

  2. University of Rome “G. Marconi”, Rome, Italy

    Torello M. Lotti

  3. Centro Studi per la Ricerca Multidisciplinare Rigenerativa (CSRMR), Rome, Italy

    Torello M. Lotti

  4. Unit of Dermatology, University of Pisa, Pisa, Italy

    Angelo Massimiliano D’Erme

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Zouboulis, C.C. (2015). Adamantiades-Behçet Disease. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45139-7_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45138-0

  • Online ISBN: 978-3-662-45139-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation